ARA-290 for Nerve Repair: What Trials Show (2026)

Neuropathic Pain Reduction

The 2013 sarcoidosis trial reported that 28 days of ARA 290 improved neuropathic symptoms and raised thresholds for painful thermal stimuli, with improvement sustained through 16 weeks of follow-up (Dahan et al., 2013). In the later dose-ranging study, subjects with moderate-to-severe baseline pain reported clinically meaningful, placebo-corrected pain reductions — strongest in the 4 mg group, though the pain endpoint did not reach statistical significance across the full sample (Culver et al., 2017). The pain signal is real but more modest than the objective nerve-fiber data.

Metabolic Markers in Type 2 Diabetes

A 2015 placebo-controlled trial administered 4 mg/day ARA 290 for 28 days in type 2 diabetes patients and reported reductions in HbA1c and improvements in lipid markers that persisted through a 56-day observation period, along with reduced neuropathic symptom scores (Brines et al., 2015). Corneal nerve fiber density increased in subjects whose baseline was reduced relative to healthy controls. These are exploratory findings from a single trial — promising, but not the focus of ARA-290's development program.

Anti-Inflammatory Signaling — strong mechanism, indirect outcomes

The "anti-inflammatory peptide" framing comes from mechanism, not from a dedicated inflammation endpoint. A 2016 review describes how the innate repair receptor is upregulated in injured tissue and modulates the neurogenic inflammatory response, with ARA-290 dampening spinal microglial activation in models of neuropathy (Dahan et al., 2016). The human trials measured nerve and metabolic outcomes rather than inflammatory markers directly, so the anti-inflammatory benefit is best read as the documented mechanism behind the nerve-repair results — not a separately validated clinical claim.

No Effect on Red Blood Cells

ARA-290 was deliberately engineered to separate erythropoietin's tissue-protective signaling from its erythropoietic and thrombotic effects. Across the published trials, investigators reported no significant change in hematocrit and an excellent safety profile — the design feature that distinguishes ARA-290 from EPO itself (Brines et al., 2015).

Who Is ARA-290 Studied In?

Common research audience: sarcoidosis patients with painful small-fiber neuropathy — the indication for which ARA-290 holds FDA Orphan Drug and Fast Track designations.

Secondary research audience: type 2 diabetes patients with neuropathic symptoms, studied in a single Phase 2 trial.

These describe the populations enrolled in published trials, not a recommendation for any individual.